Literature DB >> 3304154

Treatment of human immunodeficiency virus infections.

M S Hirsch, J C Kaplan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3304154      PMCID： PMC284196          DOI： 10.1128/AAC.31.6.839

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  25 in total

1.  Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity.

Authors:  C B Pert; J M Hill; M R Ruff; R M Berman; W G Robey; L O Arthur; F W Ruscetti; W L Farrar
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

2.  Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.

Authors:  D A Cooney; M Dalal; H Mitsuya; J B McMahon; M Nadkarni; J Balzarini; S Broder; D G Johns
Journal:  Biochem Pharmacol       Date:  1986-07-01       Impact factor: 5.858

3.  In vitro suppression of HTLV-III/LAV infectivity by a combination of acyclovir and suramin.

Authors:  L Resnick; P D Markham; K Veren; S Z Salahuddin; R C Gallo
Journal:  J Infect Dis       Date:  1986-12       Impact factor: 5.226

Review 4.  Biochemistry and clinical applications of ribavirin.

Authors:  B E Gilbert; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

5.  Potent and selective anti-HTLV-III/LAV activity of 2',3'-dideoxycytidinene, the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine.

Authors:  J Balzarini; R Pauwels; P Herdewijn; E De Clercq; D A Cooney; G J Kang; M Dalal; D G Johns; S Broder
Journal:  Biochem Biophys Res Commun       Date:  1986-10-30       Impact factor: 3.575

6.  Recombinant human interferon gamma suppresses HTLV-III replication in vitro.

Authors:  H Nakashima; T Yoshida; S Harada; N Yamamoto
Journal:  Int J Cancer       Date:  1986-09-15       Impact factor: 7.396

Review 7.  Prospects for the prevention and therapy of infections with the human immunodeficiency virus.

Authors:  M Vogt; M S Hirsch
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

8.  Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine.

Authors:  R Yarchoan; G Berg; P Brouwers; M A Fischl; A R Spitzer; A Wichman; J Grafman; R V Thomas; B Safai; A Brunetti
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

9.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

10.  In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and gamma interferon.

Authors:  S M Hammer; J M Gillis; J E Groopman; R M Rose
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205
View more
  10 in total

Review 1.  Antiretroviral therapy: reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  In vitro and in vivo effects of ribavirin on human respiratory epithelium.

Authors:  L Y Han; R Wilson; S Slater; A Rutman; R C Read; N J Snell; P J Cole
Journal:  Thorax       Date:  1990-02       Impact factor: 9.139

3.  Combinations of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1.

Authors:  R F Schinazi; D L Cannon; B H Arnold; D Martino-Saltzman
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

4.  Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome.

Authors:  T W North; G L North; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

5.  In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors.

Authors:  S Hayashi; R L Fine; T C Chou; M J Currens; S Broder; H Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

6.  Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro.

Authors:  B F Eriksson; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

7.  Inhibition (in vitro) of replication and of the cytopathic effect of human immunodeficiency virus by an extract of the culture medium of Lentinus edodes mycelia.

Authors:  T S Tochikura; H Nakashima; Y Ohashi; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

8.  The synthesis of branched-chain 3'-C-cyanomethyl-2',3'-dideoxy sugar nucleosides of adenine as potential inhibitors of the human immunodeficiency virus.

Authors:  T Halmos; R Montserret; K Antonakis
Journal:  Nucleic Acids Res       Date:  1989-10-11       Impact factor: 16.971

Review 9.  Pathogenesis of human immunodeficiency virus infection and prospects for control.

Authors:  D D Ho; J C Kaplan
Journal:  Yale J Biol Med       Date:  1987 Nov-Dec

10.  Approaches to antiviral drug development.

Authors:  W H Prusoff; T S Lin; E M August; T G Wood; M E Marongiu
Journal:  Yale J Biol Med       Date:  1989 Mar-Apr
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.